Book Online
Make a Booking

RSV Vaccine (Respiratory Syncytial Virus) for older adults

RSV Vaccine (Respiratory Syncytial Virus) for older adults

This study will test a new investigational vaccine which has not been approved by Australia’s national health agency, the Therapeutic Goods Administration (TGA), for general use. It means that this vaccine is only given to people who take part in research studies.

OVERVIEW

This study will test a new investigational vaccine which has not been approved by Australia’s national health agency, the Therapeutic Goods Administration (TGA), for general use. It means that this vaccine is only given to people who take part in research studies.

The vaccine being tested in this study is made to help prevent infection from the respiratory syncytial virus (RSV).

RSV is a virus that can cause infections of the air passages. In countries with temperate climates, RSV infections are common in winter at the same time as influenza (flu). Most people may not know when they are infected with RSV specifically because the symptoms are very similar to the common cold or flu, such as:

Sometimes, RSV infections can turn into more severe cases such as:

Older adults have a higher risk of getting a severe RSV infection than younger adults.

Even though the symptoms can be similar, RSV infections and the flu are caused by different viruses. Therefore, you can still get an RSV infection even if you have been vaccinated against flu.

So far, there is no specific treatment or vaccine available against RSV in adults. Therefore developing an investigational RSV vaccine to protect older adults from RSV infection would be beneficial..

The study will run over 2.5-3 years, and there will be 4-5 visits to see the study doctor over this time which will include general check-ups. There will also be phone calls from the study team throughout the study period.

All clinic visits, and the vaccine will be free of charge, and you will be reimbursed for clinic visits and phone calls.

THE VACCINE

The RSV vaccine used in this study contains a small part of the virus that cannot cause RSV infection. These small pieces of the virus are recognized by your defence (immune) system and can help your body make defences (called “antibodies”) against the virus.

This vaccine also has a substance called “adjuvant”. The adjuvant improves the body’s response to the vaccine.

To be eligible you must be:

CONTACT US

Please contact Holdsworth House Research to register your interest and have a confidential discussion with a member of the team:

Phone: 02 8038 1044

Email: studies@holdsworthhouse.com.au

Or enter your details here to request more information.

Participants are not obligated to join a study, and are able to withdraw at any time.

Contact Details